13/3/2024: Volpara Releases Scheme Implementation Booklet and Sets Shareholder Vote for April 12th 2024

3 Minute Read

13/3/2024: Volpara Releases Scheme Implementation Booklet and Sets Shareholder Vote for April 12th 2024

After announcing the transaction with Lunit on 14/12/2023, Volpara has now set the date for the Shareholder Vote for 11am on April 12th at Minter Ellison’s Sydney offices. The Independent Expert’s Report from Grant Samuel values Volpara at $0.67 – $0.82 vs the sale price to Lunit of $1.15, which represents a 54% premium to the mid-point of the Independent Expert’s report and a 72% premium to the bottom end of the range.

Related articles

14/12/2024: D23 Announces The Sale Of Volpara (VHT.ASX) To Lunit In Korea For A$296m​

D23 was the exclusive financial advisor to Volpara.

13/3/2024: Volpara Releases Scheme Implementation Booklet and Sets Shareholder Vote for April 12th 2024

In Relation To The Proposed Acquisition Of All Of The Fully Paid Ordinary Shares In Volpara Health Technologies......

30/11/2023: D23 Hires Technology Banker Vasili Hatzis from Goldman Sachs with Extensive USA Technology Banking Experience

Wellington, NZ, 14 December 2023: Volpara Health Technologies Limited (“Volpara”, “The Group,” Or “The...

Careers with D23Capital advisory

We are always looking for dedicated and passionate professionals to join the D23Capital Advisory team. If you have financial advisory skills or business expertise, we want to hear from you.